Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects

American Journal of the Medical Sciences

Volumn 337, Issue 5, 2009, Pages 329-335

  Saketkoo, Lesley Ann ^a,b,c   Espinoza, Luis R ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL   (United States)

^c LSU Section of Rheumatology   (United States)

Author keywords

Alveolitis; Connective tissue disorders; Cyclophosphamide; High resolution computed tomography; Interstitial lung disease; Mycophenolate mofetil; Pneumonitis; Pulmonary fibrosis

Indexed keywords

CYCLOPHOSPHAMIDE; ETANERCEPT; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXYGEN; PREDNISONE; DRUG DERIVATIVE; MYCOPHENOLIC ACID;

ADULT; AGED; ARTICLE; ASPIRATION PNEUMONIA; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; FATIGUE; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; LUNG ALVEOLITIS; LUNG FUNCTION TEST; MALE; MENTAL HEALTH; NAUSEA; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; POLYMYOSITIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THORAX PAIN; VOMITING; BIOLOGICAL MODEL; CONNECTIVE TISSUE DISEASE; DISEASE COURSE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AUTOIMMUNE DISEASES; CONNECTIVE TISSUE DISEASES; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 67649124348     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31818d094b     Document Type: Article

References (37)

1. Chang B, Wigley FM, White B, et al. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003;30:2398-405.
2. Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001;56:622-7.
3. Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and der-matomyositis. Ann Rheum Dis 2004;63:297-301.
4. Suzuki A, Ohosone Y, Obana M, et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol 1994;21:33-6.
5. Metafratzi ZM, Georgiadis AN, Ioannidou CV, et al. Pulmonary involvement in patients with early rheumatoid arthritis. Scand J Rheumatol 2007;36:338-44.
6. Hubbard R, Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford) 2002;41:676-9.
7. Kocheril SV, Appleton BE, Somers EC, et al. Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum 2005;53:549-57.
8. Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
9. Marie I, Hachulla E, Cherin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002;47:614-22.
10. Toyoshima H, Kusaba T, Yamaguchi M. Cause of death in autopsied RA patients [abstract]. Ryumachi 1993;33:209-14.
11. Tashkin DP, Elashoff R, Clements PJ, et al. Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176:1026-34.
12. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS) [review].Am J Respir Crit Care Med 2000;161(2 Pt l):646-64.
13. Jindal SK, Agarwal R. Autoimmunity and interstitial lung disease. Curr Opin Pulm Med 2005;11:438-46.
14. Afeltra A, Zennaro D, Garzia P, et al. Prevalence of interstitial lung involvement in patients with connective tissue diseases assessed with high-resolution computed tomography. Scand J Rheumatol 2006;35: 388-94.
15. Liossis SNC, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 2006;45:1005-8.
16. Nihtyanova SI, Brough GM, Black CM, et al. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis. Rheumatology (Oxford) 2007;46:442-5.
17. Plastiras SC, Vlachoyiannopoulos PG, Tzelepis GE. Mycophenolate mofetil for interstitial ung disease in scleroderma [letter]. Rheumatology 2006;45:1572.
18. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006;130:30-6.
19. Zamora AC, Wolters PJ, Collard HR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008;102:150-5.
20. Mamelok R. From mechanisms to long-term benefits. Transplantation 2005;79:543-4.
21. Morath C, Schewenger V, Beimler J, et al. Anti-fibrotic actions of mycophenolic acid. Clin Transplant 2006; 20(suppl 17):25-9.
22. Rons N, Poulalhon N, Farge D, et al. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharm Exp Therap 2007;321:563-89.
23. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004;15:255-73.
24. Ihn H. Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci 2008;49:103-13.
25. Jelaska A, Korn JH. Role of apoptosis and transforming growth factor betal in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000;43:2230-9.
26. Shi-Wen X, Kennedy L, Renzoni EA, et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum 2007;56:4189-94.
27. Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 2002;14:681-5.
28. Krieg T, Abraham D, Lafyatis R. Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res Ther 2007;9(suppl 2):S4.
29. Food and Drug Administration. Cellcept (mycophenolate mofetil). 2007. Available at: www.fda.gov/medwatch/safety/2007. Accessed December 25, 2007.
30. Tashkin DP, Elashoff R, Clements PJ, et al. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
31. Mukerjee D, Kingdon E, Vanderpump M, et al. Pathophysiological insights from a case of reversible pulmonary arterial hypertension. J R Soc Med 2003;96:403-4.
32. Suzuki C, Takahashi M, Morimoto H, et al. Mycophenolate mofetil attenuates pulmonary arterial hypertension in rats. Biochem Biophys Res Commun 2006;349:781-8.
33. Shimizu H, Takahashi M, Takeda S, et al. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation 2004;77: 1661-7.
34. Hagiwara K, Sato T, Takagi-Kobayashi S, et al. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol 2007;34:1151-4.
35. Ghosh AK, Wu M, Melichian DS, et al. Novel function of PPAR-y: endogenous anti-fibrotic that ameliorates murine scleroderma and may be defective in systemic sclerosis (SSc). Annual Scientific Meeting of the American College of Rheumatology; Abstract presentation; November 2007.
36. Distler JH, Jüngel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22.
37. Cohn RD, van Erp C, Habashi JP, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007; 13: 204-10.